Recursion Pharmaceuticals's total assets for Q1 2026 were $1.34B, a decrease of -9.13% from the previous quarter. RXRX total liabilities were $314.75M for the fiscal quarter, a -8.31% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.